上海医药
(601607)
| 流通市值：467.47亿 | | | 总市值：621.52亿 |
| 流通股本：27.89亿 | | | 总股本：37.08亿 |
| 报告期 | 2026-09-30 | 2026-06-30 | 2026-03-31 | 2025-12-31 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 222,963,979,674.49 | 147,469,729,395.2 | 75,261,732,476.16 | 283,579,600,562.98 |
| 营业收入 | 222,963,979,674.49 | 147,469,729,395.2 | 75,261,732,476.16 | 283,579,600,562.98 |
| 二、营业总成本 | 216,372,977,724.38 | 142,616,534,850.19 | 72,826,169,493.52 | 276,283,476,928.98 |
| 营业成本 | 199,499,412,722.03 | 131,209,436,636.44 | 67,168,839,531.08 | 253,163,120,898.92 |
| 税金及附加 | 674,851,449.12 | 463,980,523.09 | 241,440,476.7 | 854,164,313.59 |
| 销售费用 | 9,613,197,668.03 | 6,538,197,377.23 | 3,274,911,800.54 | 13,206,178,224.37 |
| 管理费用 | 4,055,698,040.76 | 2,739,550,557.74 | 1,315,932,843.04 | 5,312,780,131.53 |
| 研发费用 | 1,515,529,376.52 | 970,861,155.68 | 468,222,755.7 | 2,340,009,450.65 |
| 财务费用 | 1,014,288,467.92 | 694,508,600.01 | 356,822,086.46 | 1,407,223,909.92 |
| 其中:利息费用 | 1,043,604,935.29 | 706,031,998.94 | 347,642,047.02 | 1,685,890,506.64 |
| 其中:利息收入 | 137,231,953.13 | 84,939,789.19 | 38,697,345.58 | 404,967,004.79 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 66,111,297.25 | 1,951,396.44 | 61,408,258.44 | 332,120,868.45 |
| 加:投资收益 | 1,007,865,149.03 | 827,279,350.09 | -14,115,317.05 | 3,170,143,585.98 |
| 资产处置收益 | 178,691,323.73 | 179,699,818.59 | 168,790,540.68 | 157,152,717.09 |
| 资产减值损失(新) | -47,895,875.81 | -28,045,168.32 | -72,021,361.87 | -1,018,555,938.73 |
| 信用减值损失(新) | -616,058,676.9 | -507,826,641.26 | -274,438,802.21 | -574,707,845.19 |
| 其他收益 | 392,596,965.76 | 313,509,813.34 | 109,280,290.91 | 579,808,611.17 |
| 四、营业利润 | 7,572,312,133.17 | 5,639,763,113.89 | 2,414,466,591.54 | 9,942,085,632.77 |
| 加:营业外收入 | 48,060,716.82 | 36,939,069.19 | 22,169,942.02 | 105,652,418.79 |
| 减:营业外支出 | 64,249,324.8 | 45,319,225.36 | 17,441,616.13 | 227,933,534.31 |
| 五、利润总额 | 7,556,123,525.19 | 5,631,382,957.72 | 2,419,194,917.43 | 9,819,804,517.25 |
| 减:所得税费用 | 1,789,791,670.94 | 1,289,726,644.68 | 569,089,009.98 | 2,846,086,835.76 |
| 六、净利润 | 5,766,331,854.25 | 4,341,656,313.04 | 1,850,105,907.45 | 6,973,717,681.49 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 5,766,331,854.25 | 4,341,656,313.04 | 1,850,105,907.45 | 6,973,717,681.49 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 4,585,963,664.17 | 3,504,447,475.63 | 1,417,757,054.07 | 5,724,557,508.41 |
| 少数股东损益 | 1,180,368,190.08 | 837,208,837.41 | 432,348,853.38 | 1,249,160,173.08 |
| 扣除非经常损益后的净利润 | 3,374,023,474.76 | 2,477,230,508.87 | 1,237,778,489.82 | 2,980,440,494.17 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 1.24 | 0.95 | 0.38 | 1.54 |
| (二)稀释每股收益 | 1.24 | 0.95 | 0.38 | 1.54 |
| 八、其他综合收益 | 13,712,476.64 | -33,890,811.1 | -16,777,788.77 | 7,600,140.48 |
| 归属于母公司股东的其他综合收益 | 13,702,631.6 | -33,088,866.83 | -18,857,590.56 | 1,308,265.94 |
| 九、综合收益总额 | 5,780,044,330.89 | 4,307,765,501.94 | 1,833,328,118.68 | 6,981,317,821.97 |
| 归属于母公司股东的综合收益总额 | 4,599,666,295.77 | 3,471,358,608.8 | 1,398,899,463.51 | 5,725,865,774.35 |
| 归属于少数股东的综合收益总额 | 1,180,378,035.12 | 836,406,893.14 | 434,428,655.17 | 1,255,452,047.62 |
| 公告日期 | 2026-10-30 | 2026-08-28 | 2026-04-30 | 2026-03-31 |
| 审计意见(境内) | | | | 标准无保留意见 |